Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin with HiVAC in Aggressive Lymphoid Malignancies
NCT00776373Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), Burkitt lymphoma (BL) and 2 more, sponsored by Abramson Cancer Center. Primary endpoints: Safety and Tolerability and Efficacy. Started Jan 2007; status: terminated.
02
Drugs
sirolimus
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)Burkitt lymphoma (BL)adult T-cell leukemia-lymphoma (ATLL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT00776373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00776373.